NZ721697B2 - Use of benzimidazole-proline derivatives - Google Patents
Use of benzimidazole-proline derivatives Download PDFInfo
- Publication number
- NZ721697B2 NZ721697B2 NZ721697A NZ72169714A NZ721697B2 NZ 721697 B2 NZ721697 B2 NZ 721697B2 NZ 721697 A NZ721697 A NZ 721697A NZ 72169714 A NZ72169714 A NZ 72169714A NZ 721697 B2 NZ721697 B2 NZ 721697B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- dementia
- compounds
- alzheimer
- methyl
- formula
- Prior art date
Links
- UBSOHWJGTKOSAS-VWMHFEHESA-N OC(=O)[C@@H]1CCCN1.c1nc2ccccc2[nH]1 Chemical class OC(=O)[C@@H]1CCCN1.c1nc2ccccc2[nH]1 UBSOHWJGTKOSAS-VWMHFEHESA-N 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 abstract description 52
- 201000010874 syndrome Diseases 0.000 abstract description 27
- 150000003839 salts Chemical class 0.000 abstract description 16
- 239000011780 sodium chloride Substances 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 4
- 206010012289 Dementia Diseases 0.000 description 52
- -1 cyclic amine Chemical class 0.000 description 20
- 206010001897 Alzheimer's disease Diseases 0.000 description 15
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 13
- 206010001497 Agitation Diseases 0.000 description 11
- 210000000221 Suprachiasmatic Nucleus Anatomy 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 102100013818 HCRT Human genes 0.000 description 9
- 101710023151 HCRT Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000004556 Brain Anatomy 0.000 description 7
- 206010012218 Delirium Diseases 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 102000008834 Orexin receptor family Human genes 0.000 description 6
- 108050000742 Orexin receptor family Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000002569 neurons Anatomy 0.000 description 6
- 239000002464 receptor antagonist Substances 0.000 description 6
- 206010057668 Cognitive disease Diseases 0.000 description 5
- 229960001948 caffeine Drugs 0.000 description 5
- 229960003987 Melatonin Drugs 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- JKEKMBGUVUKMQB-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JKEKMBGUVUKMQB-UHFFFAOYSA-N 0.000 description 4
- 230000002060 circadian Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000007958 sleep Effects 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000003542 behavioural Effects 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 150000003950 cyclic amides Chemical class 0.000 description 3
- 230000002354 daily Effects 0.000 description 3
- 230000001965 increased Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 206010014698 Endocrine disease Diseases 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- 206010021135 Hypovitaminosis Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 206010027175 Memory impairment Diseases 0.000 description 2
- 208000008466 Metabolic Disease Diseases 0.000 description 2
- 206010027951 Mood swings Diseases 0.000 description 2
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000003814 Preoptic Area Anatomy 0.000 description 2
- 206010036631 Presenile dementia Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000002667 Subdural Hematoma Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 231100000076 Toxic encephalopathy Toxicity 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 206010047627 Vitamin deficiency Diseases 0.000 description 2
- UQYZFNUUOSSNKT-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 UQYZFNUUOSSNKT-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 125000004429 atoms Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000027288 circadian rhythm Effects 0.000 description 2
- 230000035591 circadian rhythms Effects 0.000 description 2
- 230000001054 cortical Effects 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 201000010870 diseases of metabolism Diseases 0.000 description 2
- 201000001957 endocrine system disease Diseases 0.000 description 2
- 230000004634 feeding behavior Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 201000011240 frontotemporal dementia Diseases 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003340 mental Effects 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 2
- 230000001769 paralizing Effects 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- 230000002085 persistent Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 150000003147 proline derivatives Chemical class 0.000 description 2
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical class NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000002739 subcortical Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 101710039842 ADORA2A Proteins 0.000 description 1
- 108010060263 Adenosine A1 receptor Proteins 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010013950 Dysphagia Diseases 0.000 description 1
- 208000009471 Gastroesophageal Reflux Diseases 0.000 description 1
- 206010017885 Gastrooesophageal reflux disease Diseases 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 206010048533 Hypervigilance Diseases 0.000 description 1
- 210000003016 Hypothalamus Anatomy 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 210000004558 Lewy Bodies Anatomy 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N Risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 Risperidone Drugs 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042635 Suspiciousness Diseases 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000002996 emotional Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 201000006860 gastroesophageal reflux disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003284 homeostatic Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002267 hypothalamic Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000302 ischemic Effects 0.000 description 1
- 230000002197 limbic Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000002981 neuropathic Effects 0.000 description 1
- 230000000422 nocturnal Effects 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 150000004986 phenylenediamines Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000003989 repetitive behavior Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001360 synchronised Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000002110 toxicologic Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 201000004810 vascular dementia Diseases 0.000 description 1
Abstract
The present invention relates to compounds of the formula (I), wherein Ar1 and Ar2 are as described in the description and to their use as pharmaceuticals for the treatment of sundown syndrome. The invention also relates to the preparation of such compounds and of pharmaceutically acceptable salts thereof. hereof.
Description
Use of benzimidazole-proline derivatives
The present disclosure relates to novel benzimidazole-proline derivatives of formula (I) and
their use as pharmaceuticals for the treatment of sundown syndrome. Also described are
processes for the preparation of the compounds and ceutical compositions containing
one or more compounds of formula (I).
Sundown syndrome is a late-day circadian syndrome of increased confusion and
restlessness, generally in a patient with some form of dementia. Cardinal clinical signs
include increased agitation, l confusion and mood swings that typically develop as
natural light begins to fade. This disruptive behavior worsening in the late afternoon or early
evening among ia patients or elderly institutionalized patients has been reported in
the medical literature for more than 60 years (Bachman & Rabins, Annu. Rev. Med. 2006.
57:499–511). Terms used to be this phenomenon e sundowning, afternoon
sundowning, sundowner syndrome, or sundowning syndrome.
In contrast to delirium which is generally acute in onset and fluctuating in the course of the
day, sundown syndrome is defined by its temporal pattern (late-day onset and termination).
Sundown syndrome seems to occur more frequently during the middle stages of Alzheimer
dementia. ts are generally able to understand that this behavioral pattern is abnormal.
Sundown syndrome seems to subside with the progression of a patient's dementia.
About half of dementias (44%) are of Alzheimer's type ing Alzheimer dementia
(presenile dementia or senile dementia), subcortical dementia, diffuse Lewy body ia,
and frontotemporal dementia. About 20–45% of Alzheimer type patients will experience
some sort of sundowning ion. Further 47% of dementias are of vascular type including
vascular ia, multi-infarct dementia, Binswanger's dementia, boxer's dementia, and
osclerotic dementia. Remaining types of dementia (9%) are of other etiologies such as
paralytic ia, substance-induced persisting dementia, dialysis dementia, hydrocephalic
dementia, tumors, subdural hematoma, normal pressure hydrocephalus, vasculitis, Vitamin
deficiency, or endocrine and metabolic disease.
Possible etiology of sundown syndrome es the particular histopathological signs of
degeneration that are ed into Ventro l Pre-Optic area (VLPO) and Supra-
Chiasmatic Nucleus (SCN) in dementias. The SCN pacemaker is severely affected in
Alzheimer e, whereas pineal is essentially unaffected (Swaab DF, Fliers E, Partiman
TS. "The suprachiasmatic nucleus of the human brain in relation to sex, age and senile
dementia". Brain Res 1985; 342: 37–44; Zhou JN, Hofman MA, Swaab DF. "VIP neurons in
the human SCN in relation to sex, age, and Alzheimer's disease". Neurobiol Aging 1995; 16:
571–576; Swaab DF, Grundke-Iqbal I, Iqbal Ket al. "Tau and ubiquitin in the human
hypothalamus in aging and Alzheimer's disease". Brain Res 1992; 590: 9; Stopa EG,
Volicer L, Kuo-Leblanc Vet al. "Pathologic evaluation of the human suprachiasmatic s
in severe dementia". J Neuropathol Exp Neurol 1999; 58: 29–39). SCN is ated with
ting wakefulness and sleep patterns by maintaining circadian s. These rhythms
are synchronized with external dark cues and involve complex iological
regulation within the brain. Histopathological signs of geriatric disturbance in brain ian
oscillators such as SCN have been observed across several mammalian species.
The most widely prescribed pharmacological treatments for sundown syndrome - atypical
antipsychotics - have a modest but significant beneficial effect in the short-term treatment
(over 6–12 weeks) of aggression, less so on symptoms of agitation, and have limited benefits
in longer term y. Concerns are growing over the ial for serious adverse
outcomes with these treatments, including stroke and death (Ballard et al., Nat. Rev. Neurol.
, 245–255, 2009).
Previous clinical work has been published and describes medical technology with protocols
for evaluating drug s in sundown me patients; a review on trials and
methodology in agitation and aggression in dementia can be found in Ballard et al., Nat. Rev.
Neurol. 5, 245–255, 2009 (see especially table 1). Published studies are for example:
a) Cohen-Mansfield J, Garfinkel D, Lipson S. Melatonin for treatment of sundowning in
elderly persons with dementia – a preliminary study. Arch Gerontol Geriatr 2000; 31: 65–76.
b) Brusco LI, Marquez M, Cardinali DP. Melatonin treatment izes chronobiologic and
cognitive symptoms in Alzheimer's disease. Neuroendocrinol Lett 2000; 21: 39–42.
c) de Jonghe A, Korevaar JC, van Munster BC, de Rooij SE. Effectiveness of melatonin
treatment on circadian rhythm disturbances in dementia. Are there ations for delirium?
A systematic review. Int J Geriatr Psychiatry. 2010 Dec; 25(12):1201-8.
d) ti AE. Risperidone for control of agitation in dementia patients. Am J Health Syst
Pharm. 2000 May 1;57(9):862-70.
Partial effectiveness of melatonin or bright light exposure has been reported to decrease
behavioral symptoms in sundown syndrome. Consistent sleeping schedule and daily routine
can also reduce confusion and agitation. Reduction of daytime napping is recommended as
unintentionally getting too much sleep will affect nighttime sleep. ion of caffeine intake
is recommended to sundown syndrome patients.
Neuronal afferences and efferences connect alamic orexin neurons to brain areas
involved in circadian rhythm regulation (receiving day-night signals) and in cortical activation
(inducing and maintaining ess); orexin neurons also receive afferent physiological and
emotional inputs of limbic and metabolic origin. Activated orexin neurons thus regulate
alertness for adapting the organism to environmental and circadian requirements and for
accurate maintenance of homeostatic balance (Saper et al., Nature 437: 1257, 2005). The
Ventro Lateral Pre-Optic area (VLPO) and the Supra-Chiasmatic Nucleus (SCN) are
important brain clock regions that exert major inhibition on ty of orexin neurons during
the nocturnal phase. It is hypothesized that abnormally hyperactive orexin s
significantly contribute to cortical overdrive mediating hyperalertness at a given time point in
the ian cycle. Pathological orexin hyperactivity may result from deficient inhibitory input
from VLPO and SCN that should start to gradually establish in late afternoon.
Caffeine administration ses orexin levels in rat brain. Caffeine may be used as a tool to
experimentally simulate deficient tory VLPO-SCN input to hypothalamic orexin neurons.
The pharmacological action of caffeine, an adenosine A1 and A2A receptor antagonist, is to
block adenosinergic inhibition exerted by adenosinergic s upon orexin s.
It is an object of the present invention to go someway towards overcoming the prior art
problems and/or to at least provide the public with a useful chopice. The orexin receptor
antagonists disclosed herein may reverse late-day agitation simulated in animals by
afternoon caffeine administration. Electroencephalographic recordings confirm the oral
symptoms of agitation which were reduced by two of the exemplified compounds when
administered orally to rats and / or dogs.
Short description of the s:
Figure 1 shows the effect of the nd of example 7 in a coffein-induced agitation model
in the rat.
Figure 2 shows the effect of the compound of example 11 in a coffein-induced agitation
model in the rat.
Figure 3 shows the effect of the compound of example 7 in a coffein-induced agitation model
in the dog.
Summary of the invention
In a first aspect present invention provides a uUse of a compound of the formula (I):
Formula (I)
or of a pharmaceutically acceptable salt thereof,
in the manufacture of a medicament for the prevention or treatment of sundown syndrome;
wherein the compound of formula (I) is in absolute configuration (S);
Ar1 represents
, , or ;
and Ar2 represents
, , , , ,
, , , or .
Brief Description
Orexin receptor antagonists sing a 2-substituted saturated cyclic amide derivatives
(such as 2-substituted pyrrolidinecarboxamides) are known for example from
WO2008/020405, /038251, WO2008/081399, WO2008/087611, WO2008/117241,
WO2008/139416, WO2009/004584, WO2009/016560, WO2009/016564, WO2009/040730,
WO2009/104155, WO2010/004507, WO2010/038200, WO2001/096302, WO2002/044172,
WO2002/089800, /090355, WO2003/002559, WO2003/032991, WO2003/041711,
WO2003/051368, WO2003/051873, WO2004/026866, WO2004/041791, /041807,
WO2004/041816, /003993, WO2009/003997, WO2009/124956, WO2010/060470,
WO2010/060471, WO2010/060472, WO2010/063662, /063663, WO2010/072722,
WO2010/122151, and WO2008/150364. A particular pyrrolidine derived compound is
sed in Langmead et. al, Brit. J. Pharmacol. 2004, 141, 340-346 as being highly orexin-1
selective. WO2003/002561 discloses certain l cyclic amine derivatives, encompassing
benzimidazolyl-methyl substituted pyrrolidine tives, as orexin receptor antagonists.
There is no mention of sundown syndrome in WO2003/002561. e the great number of
prior art orexin receptor antagonist compounds and their high structural ility, all
compounds share a common ural feature, i.e. in position 2 of the saturated cyclic amide
a linker group such as at least a methylene group (or longer groups such as -CH2-NH-CO-,
-CH2-NH-, -CH2-O-, -CH2-S-, etc.) link the cyclic amide to the respective aromatic ring system
substituent. It has now surprisingly been found that, despite the ntial conformational
changes that may be expected from the removal of a linker between two rigid structural
elements, the present compounds, that have a idazole ring directly attached to a
pyrrolidine amide in position 2, are potent orexin receptor antagonists.
Also described are certain benzimidazole-proline derivatives, which are potent non-peptide
antagonists of human orexin receptors for use in the prevention or treatment of sundown
syndrome.
1) A first embodiment described herein relates to compounds of the formula (I):
Formula (I)
for use in the prevention or treatment of sundown syndrome;
wherein the compounds of formula (I) are in absolute configuration (S);
Ar1 represents
, , or ;
and Ar2 represents
, , , , ,
, , , or .
2) A second embodiment relates to compounds of formula (I) according to embodiment 1) for
use according to embodiment 1), wherein the compound is:
-(5-Chloromethyl-1H-benzoimidazolyl)methyl-pyrrolidinyl]-(5-methylpyrimidinyl-phenyl)-
methanone;
[(S)(5-Bromomethyl-1H-benzoimidazolyl)methyl-pyrrolidinyl]-(5-methyl[1,2,3]triazolyl-phenyl)-
methanone;
[(S)(5-Bromomethyl-1H-benzoimidazolyl)methyl-pyrrolidinyl]-(5-methylpyrimidinyl-phenyl)-
methanone;
[(S)(5-Chloromethyl-1H-benzoimidazolyl)methyl-pyrrolidinyl]-(5-methoxy[1,2,3]triazolylphenyl
)-methanone;
[(S)(6-Bromofluoro-1H-benzoimidazolyl)methyl-pyrrolidinyl]-(5-methyl[1,2,3]triazolyl-phenyl)-
methanone;
[(S)(5,6-Dimethoxy-1H-benzoimidazolyl)methyl-pyrrolidinyl]-(5-methyl[1,2,3]triazolyl-phenyl)-
methanone;
[(S)(5,6-Dimethoxy-1H-benzoimidazolyl)methyl-pyrrolidinyl]-(5-methylpyrazolyl-phenyl)-
one;
[(S)(5,6-Dimethoxy-1H-benzoimidazolyl)methyl-pyrrolidinyl]-(5-methoxy[1,2,3]triazolyl-phenyl)-
methanone;
[(S)(6-Chlorotrifluoromethyl-1H-benzoimidazolyl)methyl-pyrrolidinyl]-(5-methyl[1,2,3]triazolylphenyl
)-methanone;
(5-Methyl[1,2,3]triazolyl-phenyl)-[(S)methyl(5-trifluoromethyl-1H-benzoimidazolyl)-pyrrolidinyl]-
methanone; or
(5-Methyl[1,2,3]triazolyl-phenyl)-[(S)methyl(5-trifluoromethoxy-1H-benzoimidazolyl)-pyrrolidinyl]-
methanone.
3) A third ment relates to compounds according to embodiment 1) for use according
to embodiment 1), n the compound is:
[(S)(5-Bromomethyl-1H-benzoimidazolyl)methyl-pyrrolidinyl]-(5-methylpyrimidinyl-phenyl)-
methanone.
4) A fourth embodiment relates to compounds according to embodiment 1) for use according
to embodiment 1), wherein the compound is:
[(S)(5-Chloromethyl-1H-benzoimidazolyl)methyl-pyrrolidinyl]-(5-methoxy[1,2,3]triazolylphenyl
)-methanone.
The compounds of formula (I) n at least one stereogenic center which is situated in
on 2 of the pyrrolidine moiety. The absolute configuration of the pyrrolidine moiety of the
present compounds is as depicted in formula (I); i.e. said chiral center is in te (S)
configuration.
In addition, it is well understood that the benzimidazole moiety Ar2 of the present nds
ents tautomeric forms. Thus, substituents of the benzimidazole moiety may be
ed in the position(s) ortho to the bridgehead atoms (i.e. attached in position(s) 4 and/or
7), and/or in the position(s) meta to the bridgehead atoms, (i.e. attached in position(s) 5
and/or 6). It is understood that the two ortho, and, respectively, the two meta positions are
considered equivalent. For example, the group 5-chloromethyl-1H-benzoimidazolyl is
understood to signify the same group as 6-chloromethyl-1H-benzoimidazolyl, 5-chloro-
4-methyl-3H-benzoimidazolyl and 6-chloromethyl-3H-benzoimidazolyl.
In this patent ation, a dotted line shows the point of attachment of the radical drawn.
For example, the radical drawn below
represents a 5-methyl(2-triazolyl)-phenyl group.
Where the plural form is used for compounds, salts, ceutical compositions, diseases
and the like, this is ed to mean also a single compound, salt, or the like.
Any reference to compounds of a (I) is to be understood as referring also to the salts
(and especially the pharmaceutically acceptable salts) of such compounds, as appropriate
and expedient.
The term "pharmaceutically acceptable salts" refers to salts that retain the desired biological
activity of the subject compound and exhibit minimal undesired toxicological effects. Such
salts include inorganic or organic acid and/or base addition salts depending on the presence
of basic and/or acidic groups in the subject nd. For reference see for e
ook of Pharmaceutical Salts. Properties, Selection and Use.”, P. Heinrich Stahl,
Camille G. Wermuth (Eds.), Wiley-VCH, 2008; and “Pharmaceutical Salts and Co-crystals”,
Johan Wouters and Luc Quéré (Eds.), RSC Publishing, 2012. A preferred pharmaceutically
acceptable salt is the hydrochloric acid salt.
Sundown syndrome is defined as a late-day (i.e. afternoon and / or evening hours, especially
afternoon hours) circadian syndrome of increased confusion and restlessness in a patient,
wherein in general said t has some form of dementia. Cardinal clinical signs include
increased agitation, general confusion and mood swings that typically develop as natural
light begins to fade. The term "late day" ed to herein relates to the afternoon and
evening, notably the time about sunset and later (but not including the night / the sleep time);
for example the time from about 4 pm to about 10 pm, especially from about 4 pm to about 9
pm. In one sub-embodiment, the term relates to the oon, especially from about 4 pm to
about 7 pm; in r sub-embodiment the term relates to the evening, especially from
about 7 pm to about 10 pm.
Dementias include notably dementias of Alzheimer's type ing: Alzheimer dementia
(presenile ia or senile dementia), subcortical ia, diffuse Lewy body dementia,
and frontotemporal dementia. Dementias further include dementias of vascular type such as:
vascular dementia, multi-infarct dementia, Binswanger's dementia, boxer's dementia,
osclerotic dementia. Remaining types of dementia (9%) are of other gies such as
paralytic dementia, substance-induced persisting dementia, dialysis dementia, hydrocephalic
ia, and dementias due to tumors, subdural hematoma, normal pressure
hydrocephalus, vasculitis, Vitamin deficiency, or endocrine or metabolic disease. In the
context of the present disclosure, the term preferably refers to dementias of Alzheimer's type,
especially mer dementia.It is understood that the term dementia also includes any
combination of the above listed types of dementias.
In a sub-embodiment, dementia especially refers to middle stages of dementias of
Alzheimer's type (especially to middle stages of mer dementia) in which stages
n syndrome appears to occur more frequently and / or of mixed dementia [a form of
dementia combining neuropathological protein deposits (associated with Alzheimer
dementia) with a dementia of vascular type]. In a preferred sub-embodiment, dementia refers
to middle stages of dementias of Alzheimer's type (especially to middle stages of Alzheimer
dementia).
Stages of dementias of mer's type may be defined as follows in the entioned
middle stages of dementias of Alzheimer's type (especially middle stages of
Alzheimer dementia) refer to stages 3 to 6, preferably stages 3 to 5, in particular to stages 3
and 4 as defined below, and n pre-senile dementia may be defined as corresponding
to stages 1 to 4, in particular to stages 3 and 4, below):
Stage 1: No ment (normal function); The person does not experience any memory
problems. An interview with a medical professional does not show any evidence of
symptoms of dementia. Stage 2: Very mild cognitive decline (may be normal age-related
s or earliest signs of a dementia, e.g. of Alzheimer's type): The person may feel as if
he or she is having memory lapses (e.g. forgetting familiar words or the location of everyday
objects). But at this stage, no symptoms of dementia can be detected during a medical
examination or by friends, family or co-workers. Stage 3: Mild ive decline (dementia,
e.g. of Alzheimer's type can be diagnosed in some, but not all duals with these
symptoms): Friends, family or co-workers begin to notice difficulties. During a detailed
medical interview, doctors may be able to detect problems in memory or tration.
Common stage 3 difficulties include: noticeable problems coming up with the right word or
name; trouble remembering names when introduced to new people; having noticeably
greater difficulty performing tasks in social or work settings; forgetting material that one has
just read; losing or misplacing a valuable object; increasing trouble with planning or
organizing. Stage 4: Moderate cognitive decline: At this point, a careful medical interview
should be able to detect clear-cut symptoms in several areas: forgetfulness of recent events;
impaired ability to perform challenging mental arithmetic; greater difficulty ming
complex tasks, such as planning dinner for guests, paying bills or managing finances;
forgetfulness about one's own personal history; becoming moody or withdrawn, especially in
socially or mentally challenging situations. Stage 5: Moderately severe cognitive decline:
gaps in memory and ng are noticeable, and individuals begin to need help with day-today
activities. At this stage, those with a dementia, e.g. of Alzheimer's type may be unable to
recall their own address or one number or the high school or college from which they
graduated; become confused about where they are or what day it is; have trouble with less
nging mental arithmetic; need help choosing proper clothing for the season or the
occasion; still remember significant details about themselves and their family; still require no
assistance with eating or using the toilet. Stage 6: Severe cognitive decline: Memory
continues to worsen, personality changes may take place and individuals need extensive
help with daily activities. At this stage, individuals may lose awareness of recent ences
as well as of their surroundings; remember their own name but have difficulty with their
personal history; distinguish ar and unfamiliar faces but have trouble remembering the
name of a spouse or caregiver; need help dressing properly and may, without supervision,
make mistakes such as putting pyjamas over daytime clothes or shoes on the wrong feet;
experience major changes in sleep patterns (e.g. sleeping during the day and becoming
ss at night); need help handling s of toileting; have increasingly frequent trouble
controlling their bladder or bowels; experience major personality and behavioral changes,
including suspiciousness and ons (such as ing that their caregiver is an impostor)
or compulsive, repetitive behavior like hand-wringing or tissue shredding; tend to wander or
become lost. Stage 7: Very severe cognitive decline: In the final stage of e.g. Alzheimer
dementia, individuals lose the ability to respond to their environment, to carry on a
conversation and, eventually, to control movement. They may still say words or phrases. At
this stage, individuals need help with much of their daily personal care, including eating or
using the . They may also lose the ability to smile, to sit without support and to hold their
heads up. Reflexes become abnormal, muscles grow rigid, swallowing impaired.
5) A fifth ment thus relates to compounds according to any one of embodiments 1) to
4) for use according to embodiment 1), n the compound is used for the prevention or
treatment of sundown syndrome in a patient who has some form of dementia.
Medical factors which may contribute to the development of sundown syndrome said patients
expressing some form of dementia may be chronic pain (e.g. due to arthritis or malignancy)
organ systemic disorders (e.g. tive heart failure, ischemic heart se, asthma,
chronic obstructive pulmonary disease, gastroesophageal reflux, incontinence, benign
prostatic hypertrophy), psychiatric conditions (e.g. depression, anxiety, sis), and
effects of medication.
6) A r ment relates to compounds according to any one of embodiments 1) to 4)
for use according to embodiment 5), wherein said patient has a dementia of Alzheimer's
type.
7) A further embodiment relates to nds according to any one of embodiments 1) to 4)
for use according to embodiment 5), n said patient has Alzheimer dementia.
8) A further embodiment relates to compounds according to any one of embodiments 1) to 4)
for use according to embodiment 5), wherein said patient has middle stage dementia of
Alzheimer's type (especially middle stage Alzheimer dementia).
9) A further embodiment relates to compounds according to any one of embodiments 1) to 4)
for use according to any one of embodiments 1) to 8), wherein said sundown syndrome is
afternoon sundown syndrome (wherein afternoon is especially defined as the intervall from
about 4 pm to about 7 pm).
) A further ment relates to compounds according to any one of embodiments 1) to
4) for use according to any one of embodiments 1) to 8), wherein said n syndrome is
evening sundown syndrome (wherein afternoon is especially defined as the intervall from
about 7 pm to about 10 pm).
Also described are compounds of the formula (I) as d in embodiment 1), or to such
compounds further limited by the characteristics of any one of ments 2) to 4), under
consideration of their respective dependencies; to pharmaceutically acceptable salts thereof;
and to the use of such compounds as medicaments in the ent of sundown syndrome
according to any one of embodiments 1) to 10). For avoidance of any doubt, the following
embodiments are thus possible and intended and herewith specifically disclosed in
individualized form:
1, 2+1, 3+1, 4+1, 5+1, 5+2+1, 5+3+1, 5+4+1, 6+5+1, 6+5+2+1, 6+5+3+1, 6+5+4+1, 7+5+1,
7+5+2+1, 7+5+3+1, 7+5+4+1, 8+5+1, 8+5+2+1, 8+5+3+1, 1, 9+1, 9+2+1, 9+3+1,
9+4+1, 9+5+1, 9+5+2+1, 9+5+3+1, 9+5+4+1, 1, 9+6+5+2+1, 3+1,
4+1, 9+7+5+1, 9+7+5+2+1, 9+7+5+3+1, 9+7+5+4+1, 9+8+5+1, 9+8+5+2+1,
9+8+5+3+1, 9+8+5+4+1, 10+1, 10+2+1, 10+3+1, 10+4+1, 10+5+1, 10+5+2+1, 10+5+3+1,
+5+4+1, 10+6+5+1, 10+6+5+2+1, 10+6+5+3+1, 10+6+5+4+1, 10+7+5+1, 10+7+5+2+1,
10+7+5+3+1, 10+7+5+4+1, 10+8+5+1, 10+8+5+2+1, 10+8+5+3+1, 10+8+5+4+1.
In the list above the numbers refer to the embodiments according to their numbering
provided hereinabove whereas “+” indicates the dependency from another embodiment. The
ent individualized embodiments are separated by . In other words, “10+7+5+1”
for example refers to embodiment 10) depending on embodiment 7), depending on
embodiment 5), depending on embodiment 1), i.e. embodiment “10+7+5+1” corresponds to the
compounds of formula (I) according to embodiment 1) further limited by all the features of the
embodiments 5), 7), and 10).
The compounds of formula (I) according to any one of embodiments 1) to 4) and their
ceutically acceptable salts can be used as medicaments for the prevention or
treatment of sundown syndrome, e.g. in the form of pharmaceutical compositions for enteral
(such especially oral) or parenteral stration ding topical ation or inhalation).
The production of the pharmaceutical compositions can be effected in a manner which will be
familiar to any person d in the art (see for e Remington, The Science and
Practice of Pharmacy, 21st Edition (2005), Part 5, “Pharmaceutical Manufacturing”
[published by Lippincott Williams & Wilkins]) by bringing the described compounds of
formulae (I), (II) and (III) or their pharmaceutically acceptable salts, optionally in combination
with other therapeutically valuable substances, into a galenical stration form together
with suitable, non-toxic, inert, eutically compatible solid or liquid carrier materials and,
if desired, usual pharmaceutical adjuvants.
Also described is a method for the ent of a er mentioned herein comprising
administering to a subject a pharmaceutically active amount of a compound of formula (I) as
defined in any one of embodiments 1) to 4).
In a red embodiment of the disclosure, the administered amount of such a compound
of formula (I) according to any one of embodiments 1) to 4) is comprised between 1 mg and
1000 mg per day, ularly between 5 mg and 400 mg per day, more particularly n
mg and 200 mg per day.
Whenever the word “between” is used to describe a numerical range, it is to be understood
that the end points of the indicated range are explicitly included in the range. For example: if
a temperature range is described to be between 40 ºC and 80 ºC, this means that the end
points 40 ºC and 80 ºC are ed in the range; or if a variable is defined as being an
integer between 1 and 4, this means that the variable is the integer 1, 2, 3, or 4.
The term “about” placed before a cal value “X” refers in the current application to an
al extending from X minus 10% of X to X plus 10% of X, and ably to an interval
ing from X minus 5% of X to X plus 5% of X. In the particular case of temperatures,
the term “about” placed before a temperature “Y” refers in the current application to an
interval extending from the temperature Y minus 10ºC to Y plus 10ºC, and preferably to an
interval extending from Y minus 5ºC to Y plus 5ºC. Besides, the term “room temperature” as
used herein refers to a temperature of about 25°C. In the particular case of time points, the
term “about” placed before a certain time point “Y” refers in the current application to an
interval extending from the time point Y minus 1 hour to Y plus 1 hour, and preferably to an
interval extending from Y minus 30 minutes to Y plus 30 s.
For avoidance of any doubt, if compounds are described as useful for the prevention or
treatment of certain diseases, such compounds are likewise suitable for use in the
preparation of a medicament for the prevention or treatment of said diseases.
Preparation of compounds of formula (I):
The compounds of formula (I) can be prepared by the methods given below, by the methods
given in the experimental part below or by analogous methods. Optimum reaction conditions
may vary with the particular reactants or solvents used, but such conditions can be
determined by a person skilled in the art by routine optimisation procedures. In some cases
the final product may be further modified, for example, by manipulation of substituents to give
a new final product. These lations may include, but are not limited to, reduction,
oxidation, alkylation, ion, and hydrolysis reactions which are commonly known to those
skilled in the art. In some cases the order of carrying out the following reaction s,
and/or reaction steps, may be varied to facilitate the reaction or to avoid unwanted reaction
products.
Compounds of formula (I) described herein can be prepared according to the general
sequence of reactions outlined below wherein Ar1 and Ar2 are as defined for formula (I). The
generic substituent (R)n refers to the tuents of the benzimidazole group Ar2 as defined
for the compounds of formula (I).
There are two general tic approaches towards the compounds of formula (I).
OH CH3
N OH H
H N N
O N
a b Boc O c (R)n
Boc O
H CH3
N H
N N CH3
N H
N H N
Ar1 O N N
(R)n x HCl
f (R)n d Boc N
(R)n
A first synthetic approach 1 may start with a Boc-protection of the respective proline
tive a under standard conditions, e.g. by dissolving the proline a in a solvent such as
DCM or THF and adding a base to the solution, for example DIPEA, TEA or aq. Na2CO3
followed by the addition of Boc2O. The reaction is performed at RT and is usually complete
within a few hours and results in the Boc-protected proline derivative b. The protected proline
derivative b (which is also cially available) is then coupled under standard amide
coupling conditions with the appropriate phenylene-diamine derivative, e.g. in a t such
as THF, DCM or DMF in the presence of a ng agent such as HBTU or TBTU or the like
and a base, for example DIPEA or TEA to give compound c. Ring closure to obtain the
benzimidazole derivative d is achieved for example by dissolving the precursor c in AcOH
and heating at 100°C for 1 h. Compound d is Boc-deprotected under rd acidic
conditions such as 4M HCl in dioxane, or TFA in DCM, to give precursor e which is
converted into the final compound f by an amide ng on with Ar1-COOH, e.g. in a
solvent such as THF, DMF or DCM in the ce of a coupling agent such as TBTU,
HBTU, HATU, EDC or the like and a base such as DIPEA, TEA or N-methylmorpholine.
CH3 CH3 CH3
N O O
H N
O H
a O g O h
Ar1 O
H CH3 H CH3
N N
N OH
O (R)n N
Ar1 O
(R)n Ar1 O O
H2N Ar1 O i
An alternative synthetic ch 2 may start with an esterification (usually methyl ester
formation) of the proline derivative a, e.g. by dissolving the starting material in THF and
adding 5 equivalents of the respective alcohol (usually MeOH) followed by the addition of
EDC and DMAP. The methyl-ester derivative g (which is also commercially ble) is then
ed with Ar1-COOH using standard amide coupling conditions such as those described
above to result in intermediate h. Ester hydrolysis under standard conditions, e.g. by
dissolving the ester derivative h in THF / MeOH =
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2013060630 | 2013-12-04 | ||
PCT/IB2014/066548 WO2015083094A1 (en) | 2013-12-04 | 2014-12-03 | Use of benzimidazole-proline derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ721697A NZ721697A (en) | 2021-09-24 |
NZ721697B2 true NZ721697B2 (en) | 2022-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014358766B2 (en) | Use of benzimidazole-proline derivatives | |
CA2889196C (en) | Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof | |
CA3123897C (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
CN103313712B (en) | For treating the pyridyl derivatives of cognitive disorder, compositions and method | |
JP2016528266A (en) | V1a antagonists for treating phase shift sleep disorders | |
CN106349228B (en) | Substituted quianzolinones and its preparation method and application | |
JP2019516696A (en) | Combination of pure 5-HT6 receptor antagonists with NMDA receptor antagonists | |
NZ721697B2 (en) | Use of benzimidazole-proline derivatives | |
CN107735094A (en) | The new application of the inhibitor of cystine glutamate transporter | |
BR112019012821A2 (en) | benzodiazepine derivatives, compositions and methods for the treatment of cognitive impairment | |
US20230000859A1 (en) | Methods for treating behavioral and psychological symptoms in patients with dementia | |
BR112016014564B1 (en) | COMPOUNDS DERIVED FROM BENZODIAZEPINE, PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF COGNITIVE DEFICIENCY ASSOCIATED WITH A DISORDER OF THE CENTRAL NERVOUS SYSTEM |